@article {7879,
	title = {Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/β-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: A hellenic Cooperative Oncology Group (HECOG) st},
	journal = {Anticancer Research},
	volume = {28},
	year = {2008},
	note = {Cited By :7Export Date: 21 February 2017},
	month = {2008},
	pages = {2479 - 2486},
	abstract = {Background: Cycloxygenase (COX)-2 has been associated with proliferation, apoptosis and angiogenesis in urothelial cancer. The prognostic significance of COX-2 in patients who received adjuvant chemotherapy for urothelial cancer was examined. Patients and Methods: Expression of COX-2, p53, ki67, β-catenin, vascular endothelial growth factor (VEGF) and microvessel density (MVD) were studied retrospectively in 59 patients with urothelial cancer (pT3, pT4, N+) who had undergone surgery. The patients had subsequently received adjuvant chemotherapy. Results: Thirty-eight out of 59 cases (64\% ) were positive for COX-2. COX-2 was not associated either with progression-free survival (PFS) or overall survival (OS). MVD levels >=47 were associated with longer median PFS compared with lower levels (not reached vs. 13 months [95\% CI: 8-18], p=0.048). The median PFS for patients with β-catenin nuclear accumulation and COX-2 expression was 6 months (95\% CI: 4-7) compared with 19 months (95\% CI: 14-23) for neither or only one of these factors (p=0.018). Conclusion: MVD may be a useful indicator of relapse in high-risk urothelial cancer treated with adjuvant chemotherapy.},
	keywords = {Bladder cancer, CD105, COX-2, MVD, β-Catenin},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-48849100188\&partnerID=40\&md5=3b3bd39cab6046ef7552419c912027fd},
	author = {Bamias, A. and Kyriakou, F. and Chorti, M. and Kavantzas, N. and Noni, A. and Kyroudi-Voulgari, A. and Rontoyianni, D. and Kastritis, E. and Xiros, N. and Patsouris, E.S. and Murray, S. and Tamvakis, N. and Dimopoulos, M.A.}
}
